

Crotaline Snakebite Management: The Role of CroFab® Crotalidae Polyvalent Immune Fab (Ovine)

Guest Speaker: Jami Johnson, PharmD, DABAT

Assistant Managing Director & Clinical Instructor, Oklahoma Center for Poison & Drug Information
Adjunct Assistant Professor, University of Oklahoma College of Pharmacy

Location:

The West Table Restaurant

1204 Broadway St. #103

Lubbock, TX 79401

Thursday, March 28, 2019

Registration: 6:30pm | Presentation: 7:00pm



TO REGISTER: Scan the QR code with your smart-phone camera and complete your registration (or visit: <https://www.surveymonkey.com/r/3ZY2DZS>). For any questions, please contact your BTG Territory Sales Manager, Kevin Rogers at Kevin.Rogers@btgplc.com or call/text 806-401-5033.

Indication


CroFab® Crotalidae Polyvalent Immune Fab (Ovine) is a sheep-derived antivenin indicated for the management of adult and pediatric patients with North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes which includes rattlesnakes, copperheads and cottonmouths/water moccasins.

Important Safety Information

The most common adverse reactions reported in the clinical studies were urticaria, rash and nausea. Adverse reactions involving the skin and appendages (primarily rash, urticaria, and pruritus) were reported in 12 of the 42 patients. Two patients had a severe allergic reaction (severe hives and a severe rash and pruritus) following treatment and one patient discontinued CroFab® due to an allergic reaction. Anaphylaxis and hypersensitivity reactions can occur, and patients should be monitored closely during treatment. CroFab® should not be administered to patients with a known history of hypersensitivity to papaya or papain unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available.

In clinical trials, recurrent coagulopathy (the return of a coagulation abnormality after it has been successfully treated with antivenin), characterized by decreased fibrinogen, decreased platelets and elevated prothrombin time, occurred in approximately half of the patients studied; one patient required rehospitalization and additional antivenin administration. Recurrent coagulopathy may persist for 1 to 2 weeks or more. Patients who experience coagulopathy due to snakebite should be monitored for recurrent coagulopathy for up to 1 week or longer. During this period, the physician should carefully assess the need for re-treatment with CroFab® and use of any type of anticoagulant or anti-platelet drug.

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this promotional program is limited to healthcare professionals. As such, attendance by guests or spouses is not permitted. Certain federal and/or state laws as well as policies of your institution may limit your ability to accept the modest meal provided during this educational program.



BTG International Inc. © All rights reserved NA-CRF-2018-0439 March 2018

BTG and the BTG roundel logo are registered trademarks of BTG International Ltd. CroFab is a registered trademark of BTG International Inc.

CROFab®
crotalidae polyvalent immune fab (ovine)